Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018;16(1):17-28.
doi: 10.2174/1570159X15666170504123316.

Drug-Resistant Epilepsy and Surgery

Jiyao Sheng  1 , Shui Liu  1 , Hanjiao Qin  1 , Bingjin Li  1 , Xuewen Zhang  1
Affiliations
Review

Drug-Resistant Epilepsy and Surgery

Jiyao Sheng et al. Curr Neuropharmacol. 2018.

Abstract

Background: Epilepsy is a chronic brain disease that is caused by various factors and characterized by recurrent, episodic and temporary central nervous system dysfunction which results due to excessive discharge of brain neurons. In the past decades, despite the continuous development of antiepileptic drugs, there are still many patients with epilepsy progressing to drugresistant epilepsy. Currently, surgical treatment is one of important way to cure drug-resistant epilepsy.

Methods: Data were collected from Web of Science, Medline, Pubmed, through searching of these keywords: "surgery" and "drug-resistant epilepsy".

Results: An increasing number of studies have shown that surgery plays an important role in the treatment of drug-resistant epilepsy. Moreover, the comprehensive treatment mainly based on surgery can achieve the remission and even cure of drug-resistant epilepsy.

Conclusion: In this review, we discuss the pathogenesis of drug-resistant epilepsy and the comprehensive treatment mainly based on surgery; this review may provide a reference for the clinical treatment of drug-resistant epilepsy.

Keywords: Drug-resistant; brain; epilepsy; neuron; surgery; treatment.

PubMed Disclaimer

References

    1. Fisher R.S., Acevedo C., Arzimanoglou A., Bogacz A., Cross J.H., Elger C.E., Engel J., Jr, Forsgren L., French J.A., Glynn M., Hesdorffer D.C., Lee B.I., Mathern G.W., Moshé S.L., Perucca E., Scheffer I.E., Tomson T., Watanabe M., Wiebe S. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475–482. [http://dx.doi.org/10.1111/epi.12550]. [PMID: 24730690]. - PubMed
    1. Murray G.J. Global Comparative Assessments in the Health Sector: Disease Burden. Expenditure, Intervention Packages; 1994.
    1. Kwan P., Brodie M.J. Early identification of refractory epilepsy. N. Engl. J. Med. 2000;342(5):314–319. [http://dx.doi.org/10.1056/ NEJM200002033420503]. [PMID: 10660394]. - PubMed
    1. Kwan P., Arzimanoglou A., Berg A.T., Brodie M.J., Allen H.W., Mathern G., Moshé S.L., Perucca E., Wiebe S., French J. Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia. 2010;51(6):1069–1077. [http://dx.doi.org/10.1111/ j.1528-1167.2009.02397.x]. [PMID: 19889013]. - PubMed
    1. Löscher W., Luna-Tortós C., Römermann K., Fedrowitz M. Do ATP-binding cassette transporters cause pharmacoresistance in epilepsy? Problems and approaches in determining which antiepileptic drugs are affected. Curr. Pharm. Des. 2011;17(26):2808–2828. [http://dx.doi.org/10.2174/138161211797440212]. [PMID: 21827408]. - PubMed

LinkOut - more resources